Standard BioTools Inc.

NASDAQ:LAB

Medical - Devices

Healthcare
$0.57 +3.38%

+$0.03 today

Market cap
$225.03M
Beta
1.38
P/E (TTM)
-3.5
EPS (TTM)
-$0.24
52W Low $0.79High $1.72

Volume 0.70M

Average 2.91M

LAB Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Standard BioTools Inc.NASDAQ: LAB

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables declines year over year

Q1 FY2026 accounts receivables of $1.86M (cash outflow) fell 8.1% year over year, ahead of the -82.4% change in trailing-twelve-month accounts receivables.

Context

  • Accounts receivables amounted to 1.6% of revenue in FY2025, down 3.5 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -8.1% holds above the trailing-twelve-month pace of -82.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.86M-127.6% QoQ
Last fiscal yearDec 2025
-$1.36M-115.2% YoY
LTMMar 2026
$1.1M-82.4% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.1%——
1 year-115.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(1.36M) USD
Year-over-year change
-115.2%

Accounts Receivables vs competitors

How LAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -82.4% is the 7th highest of 9, against a peer median of +18.0%.
  • Accounts receivables amounts to 1.3% of revenue for LAB, versus a peer median of 0.8%.
LAB Competitors
Accounts Receivables for LAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SYSo-Young International Inc.LTM Dec 2025CN¥29.72M CNY—+29.9%2.0%
KIDSOrthoPediatrics Corp.LTM Mar 2026$8.05M USD+8.8%+33.0%3.3%
AVNSAvanos Medical, Inc.LTM Mar 2026$5.5M USD-46.6%—0.8%
CBLLCeriBell, Inc.LTM Mar 2026$4.33M USD+27.2%+1.8%4.6%
VREXVarex Imaging CorporationLTM Apr 2026$3.7M USD-169.8%—0.4%
CTKBCytek Biosciences, Inc.LTM Mar 2026$3.56M USD+210.9%—1.7%
BVSBioventus Inc.LTM Mar 2026$2.6M USD-979.1%-62.7%0.5%
LABStandard BioTools Inc.LTM Mar 2026$1.1M USD-82.4%—1.3%
ADCTADC Therapeutics S.A.LTM Mar 2026$516.86K USD+106.0%-41.0%0.7%
TMCITreace Medical Concepts, Inc.LTM Mar 2026$306K USD+107.3%-42.6%0.1%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$0 USD———
Peer median (excluding LAB) —+18.0%-19.6%0.8%

Competitors are the stored peer set for LAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(59.24M)(190.1M)(74.66M)(138.89M)(74.9M)
Depreciation & Amortization16.2M15.03M15.18M16.86M1.72M
Deferred Income Tax00000
Stock-Based Compensation16.1M14.88M13.12M31.73M29.61M
Change in Working Capital(18.01M)(12.35M)1.79M(12.08M)(44.98M)
Accounts Receivables6.73M1.06M(2.99M)8.97M(1.36M)
Inventory(4.78M)(8.47M)(4.91M)(9.88M)(11.52M)
Accounts Payables001.62M02.44M
Other Working Capital(19.95M)(4.95M)8.07M(11.17M)(34.53M)
Other Non-Cash Items886K83.17M1.28M(41.08M)14.2M
Operating Cash Flow(44.06M)(89.37M)(43.29M)(143.45M)(74.35M)
Capital Expenditures(13.26M)(3.83M)(2.83M)(8.36M)(8.3M)
Acquisitions (Net)000278.65M0
Purchases of Investments00(94.9M)0(140.93M)
Sales of Investments00117.96M0179M
Other Investing Activities1.32M(84.3M)092.88M(5M)
Investing Cash Flow(11.95M)(88.13M)20.24M363.17M24.77M
Debt Repayment9.5M18.16M(2.08M)(63.19M)0
Common Stock Issued00001.05M
Common Stock Repurchased(1.79M)(774K)(5.41M)(40.95M)0
Dividends Paid00000
Other Financing Activities8.25M213.37M827K1.53M(484K)
Financing Cash Flow15.96M230.76M(6.81M)(102.62M)570K
Effect of Forex Changes(21K)(404K)34K(785K)842K
Net Change in Cash(40.07M)52.86M(29.83M)116.32M(48.17M)
Free Cash Flow(57.33M)(93.2M)(46.12M)(151.81M)(82.65M)

Standard BioTools Inc.

NASDAQ:LAB

Intrinsic Alpha fair value

Locked

Current Price

$0.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.